Abstract
Oral niraparib, a highly-selective, potent poly(ADP-ribose) polymerase (PARP)-1 and PARP-2 inhibitor, is approved in the USA for the maintenance treat......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
